¶¶Òõ¶ÌÊÓƵ
Back to
Dr Matthew Coleshill

Dr Matthew Coleshill

Postdoctoral Fellow

PhD (Psychology)

University of Hull, United Kingdom

Bachelor of Science (Honours) in Psychology

University of Hull, United Kingdom

Medicine & Health
The Black Dog Institute

Dr Coleshill has a research background is in health psychology, specifically the placebo effect, treatment adherence, and the evaluation of digital health interventions. His research at the Black Dog Institute has focused on evaluating a blended care mental health support service for health professionals - The Essential Network (TEN).

Beyond this, Dr Coleshill is interested in interventions to support people experiencing burnout, interventions to reduce the experience of side effects from medications or improve medication adherence, as well as research into factors affecting patient outcomes.
E-mail
m.coleshill@unsw.edu.au
Location
Black Dog Institute Hospital Road Randwick NSW 2031
  • Journal articles | 2024
    Coleshill M; Fransisca K; Du X; Black M; Newby JM; Harvey S; Christensen H; Baldwin P, 2024, 'The Essential Network (TEN): consulting stakeholders and experts to better understand implementation of a blended care mental health support services for Australian health professionals', Australian Journal of Psychology, 76,
    Journal articles | 2024
    Michael TJF; Chan JS; Hughes S; Wright DFB; Coleshill MJ; Hughes DA; Day RO; Aslani P; Stocker SL, 2024, 'The experiences and perspectives of people with gout on urate self-monitoring', Health Expectations, 27,
    Journal articles | 2024
    Michael TJF; Wright DFB; Chan JS; Coleshill MJ; Aslani P; Hughes DA; Day RO; Stocker SL, 2024, 'Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study', ACR Open Rheumatology, 6, pp. 403 - 411,
    Journal articles | 2024
    Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E, 2024, 'Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing', British Journal of Clinical Pharmacology, 90, pp. 1322 - 1332,
    Journal articles | 2024
    Schulz M; Day RO; Coleshill MJ; Briggs NE; Aung E, 2024, 'Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout', Clinical Rheumatology, 43, pp. 2943 - 2954,
    Journal articles | 2024
    Selvadurai D; Coleshill MJ; Day RO; Briggs NE; Schulz M; Reath J; Aung E, 2024, 'Patient factors and health outcomes associated with illness perceptions in people with gout', Rheumatology (United Kingdom), 63, pp. 1927 - 1937,
    Journal articles | 2024
    Storer B; Holden M; Kershaw KA; Braund TA; Chakouch C; Coleshill MJ; Haffar S; Harvey S; Sicouri G; Newby J; Murphy M, 2024, 'The prevalence of anxiety in respiratory and sleep diseases: A systematic review and meta-analysis', Respiratory Medicine, 230,
    Journal articles | 2023
    Coleshill MJ; Alagirisamy D; Patki S; Ronksley M; Black MJ; Yu S; Phillips M; Newby JM; Cockayne N; Tennant J; Harvey SB; Christensen H; Baldwin PA, 2023, 'The Essential Network (TEN): engagement and mental health insights from a digital mental health assessment tool for Australian health professionals during COVID-19', BMC Digital Health, 1, pp. 31 - 31,
    Journal articles | 2023
    Kershaw KA; Storer B; Braund T; Chakouch C; Coleshill M; Haffar S; Harvey S; Newby J; Sicouri G; Murphy M, 2023, 'The prevalence of anxiety in adult endocrinology outpatients: A systematic review and meta–analysis', Psychoneuroendocrinology, 158,
    Journal articles | 2023
    Spragg JCJ; Michael TJF; Aslani P; Coleshill MJ; Chan JS; Day RO; Stocker SL, 2023, 'Optimizing adherence to allopurinol for gout: patients' perspectives', British Journal of Clinical Pharmacology, 89, pp. 1978 - 1991,
    Journal articles | 2023
    Storer B; Kershaw KA; Braund TA; Chakouch C; Coleshill MJ; Haffar S; Harvey S; Newby J; Sicouri G; Murphy M, 2023, 'The prevalence of anxiety disorders in dermatology outpatients: A systematic review and meta-analysis', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1576 - 1586,
    Journal articles | 2023
    Storer B; Kershaw KA; Braund TA; Chakouch C; Coleshill MJ; Haffar S; Harvey S; Newby JM; Sicouri G; Murphy M, 2023, 'Global Prevalence of Anxiety in Adult Cardiology Outpatients: A Systematic Review and Meta-analysis', Current Problems in Cardiology, 48,
    Journal articles | 2023
    Wise S; Smith E; Carlos L; Coleshill M; Day RO; Melocco T; Carland JE, 2023, 'Who is asking? Requests for antimicrobial prescribing advice received by hospital pharmacists', Journal of Pharmacy Practice and Research, 53, pp. 39 - 43,
    Journal articles | 2022
    Coleshill MJ; Baldwin P; Black M; Newby J; Shrestha T; Haffar S; Mills L; Stensel A; Cockayne N; Tennant J; Harvey S; Christensen H, 2022, 'The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19', JMIR Research Protocols, 11,
    Journal articles | 2022
    Coleshill MJ; Day RO; Tam K; Kouhkamari M; Caillet V; Aung E; Kannangara DRW; Cronin P; Rodgers A; Stocker SL, 2022, 'Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions', British Journal of Clinical Pharmacology, 88, pp. 4894 - 4901,
    Journal articles | 2022
    Wise S; Coleshill MJ; Taylor N; Le M; Debono D; Day RO; Melocco T; Baysari MT; Laba TL; Carland JE, 2022, 'Australian hospital outpatient pharmacies: service adaptations during the 2020 national coronavirus disease 2019 lockdown', Journal of Pharmacy Practice and Research, 52, pp. 326 - 328,
    Journal articles | 2021
    Coleshill MJ; Aung E; Carland JE; Faasse K; Stocker S; Day RO, 2021, 'Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?', Therapeutic Innovation and Regulatory Science, 55, pp. 138 - 141,
    Journal articles | 2021
    Coleshill MJ; Sharpe L; Colagiuri B, 2021, 'No evidence that attentional bias towards pain-related words is associated with verbally induced nocebo hyperalgesia: A dot-probe study', Pain Reports, 6,
    Journal articles | 2020
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S, 2020, 'Better outcomes for patients with gout', Inflammopharmacology, 28, pp. 1395 - 1400,
    Journal articles | 2020
    Day RO; Coleshill MJ; Stocker SL; Nguyen AD; Robinson P; Aung E, 2020, 'Predictors of success in gout treatment', Journal of Rheumatology, 47, pp. 313 - 315,
    Journal articles | 2019
    Coleshill MJ; Aung E; Nguyen AD; Stocker SL; Baysari MT; Kamel B; Schulz M; McLachlan AJ; Day RO, 2019, 'Improving adherence to urate-lowering therapy in people living with gout', International Journal of Rheumatic Diseases, 22, pp. 542 - 544,
    Journal articles | 2019
    Day RO; Cohen M; Coleshill MJ; Ghinea N; Lipworth W; Maher CG; Latimer J; Lin CWC; McLachlan AJ, 2019, 'Is it ethical to prescribe paracetamol for acute low back pain and osteoarthritis?', The Lancet Rheumatology, 1, pp. e140 - e142,
    Journal articles | 2019
    Day RO; Lau W; Stocker SL; Aung E; Coleshill MJ; Schulz M; Bechara J; Carland JE; Graham GG; Williams KM; McLachlan AJ, 2019, 'Management of gout in older people', Journal of Pharmacy Practice and Research, 49, pp. 90 - 97,
    Journal articles | 2018
    Coleshill MJ; Sharpe L; Colloca L; Zachariae R; Colagiuri B, 2018, 'Placebo and Active Treatment Additivity in Placebo Analgesia: Research to Date and Future Directions', International Review of Neurobiology, 139, pp. 407 - 441,
    Journal articles | 2017
    Coleshill MJ; George DN; Mazzoni G, 2017, 'Placebo Analgesia From a Rubber Hand', Journal of Pain, 18, pp. 1067 - 1077,
  • Conference Abstracts | 2022
    Coleshill M; Baldwin P; Black M; Newby J; Shrestha T; Haffar S; Stensel A; Cockayne N; Tennant J; Harvey SB; Christensen H, 2022, 'THE ESSENTIAL NETWORK (TEN): A BLENDED MENTAL HEALTH SERVICE FOR AUSTRALIAN HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC', in AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, SAGE PUBLICATIONS LTD, Vol. 56, pp. 80 - 80,
    Preprints | 2021
    Coleshill MJ; Baldwin P; Black M; Newby J; Shrestha T; Haffar S; Mills L; Stensel A; Cockayne N; Tennant J; Harvey S; Christensen H, 2021, The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19 (Preprint),
    Conference Papers | 2021
    Mao C; Coleshill M; Day RO; Aung E, 2021, 'ADHERENCE TO URATE LOWERING THERAPY AMONG PEOPLE WITH GOUT IN AUSTRALIA', in INTERNAL MEDICINE JOURNAL, WILEY, pp. 49 - 49,
    Conference Papers | 2020
    Aung E; Coleshill M; Schulz M; Kamel B; Stocker S; Day R, 2020, 'RECRUITING PEOPLE WITH GOUT INTO A CLINICAL TRIAL IN PRIMARY CARE: THE GAPP EXPERIENCE', in INTERNAL MEDICINE JOURNAL, WILEY, pp. 42 - 42,

  • Avant Foundation ($107,844 AUD), 2023. Tackling burnout in Australian doctors by blending a custom-built digital cognitive-behavioural therapy program and specialist telehealth treatment.
  • Arthritis Australia Project Grant ($30,000 AUD), 2020. Effect of self-monitoring urate levels on adherence to allopurinol.

2017       Society for Interdisciplinary Placebo Studies Travel Award (€300 EUR)

2016       Ian Potter Foundation Travel Grant ($1000 AUD)

2013       Experimental Psychology Society Grindley Grant (£500 GBP)

2011       University of Hull 80th Anniversary PhD Scholarship

  • Evaluation of The Essential Network (TEN). TEN is a blended care mental health support service for health professionals. This research includes both quantitative and qualitative methods examining usage of TEN, barriers to health professionals engaging with TEN, as well as formal assessment of TEN and its components through observational studies and randomised-controlled trials.
  • Medication adherence in gout. This research encompasses the Gout APP (GAPP) trial, a randomised-controlled trial of a mobile application for people with gout, as well as other novel avenues for improving medication adherence in gout, such as the use of point-of-care devices. 
  • Medication side effects and the placebo/nocebo effects.